利妥昔单抗对儿童难治性肾病综合征的治疗进展

Progress of rituximab therapy on children with refractory nephrotic syndrome

难治性肾病综合征是导致儿童终末期肾脏病的主要原因之一,也是临床治疗的棘手问题.虽然包括免疫抑制剂在内的多种治疗方法已经对儿童难治性肾病综合征表现出了良好的治疗效果以及安全性,但是仍有很多患儿不能获得缓解.近年来,新型免疫抑制剂利妥昔单抗用于治疗难治性肾病综合征取得了较好效果,很多病例分析以及临床试验对利妥昔单抗治疗儿童难治性肾病综合征的有效性进行了报道.该文就该药治疗儿童难治性肾病的疗效和安全性等作一综述.

Refractory nephrotic syndrome（RNS） is one of the main causes of end-stage renal disease （ESRD） in children,which is also a difficult issue in clinic.Several therapies,including immunosuppressive agents,have been shown to be effective and safe for RNS.It is proved,however,that a substantial number of children are still refractory to treatment despite these therapies.Recently,rituximab as a new immunosuppressant has achieved good results for RNS,and a number of case reports and clinical trials have suggested that rituximab may be effective for children with RNS.This review will analyse the scientific basis for the efficacy and safety of using rituximab in children with RNS.